Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors
K. B. Williams, A. T. Larsson, B. J. Keller, K. E. Chaney, R. L. Williams, T. A. Jubenville, M. M. Bhunia, G. M. Draper, C. L. Moertel, N. Ratner, D. A. Largaespada
This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.
bioRxiv · Mar 25, 2024Cancer Biology